Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular status of PI3KCA, KRAS and BRAF in ovarian clear cell carcinoma: an analysis of 63 patients.

Journal of clinical pathology - 1 Dec 2016

Zannoni Gian Franco, Improta Giuseppina, Pettinato Angela, Brunelli Chiara, Troncone Giancarlo, Scambia Giovanni, Fraggetta Filippo

Abstract excerpt

AIMS: To evaluate the incidence of PI3KCA, KRAS and BRAF mutations in primary ovarian clear cell carcinoma (OCCC). METHODS: 63 consecutive patients, with a proven diagnosis of OCCC, according to WHO criteria, were included into the study. Pyrosequencing analysis of all three genes hotspot regions were performed on 2.5 µm sections of formalin-fixed paraffin-embedded tissue from primary OCCC. RESULTS: PI3KCA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma, Clear Cell
Share to Codon

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Incidence

Share to Nuclear Proteins

Share to Ovarian Neoplasms

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 27153872
DOI: 10.1136/jclinpath-2016-203776

Genes

KRAS
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular status of PI3KCA, KRAS and BRAF in ovarian clear cell carcinoma: an analysis of 63 patients.PMID 27153872Read ↗

Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma.Semantic proximity Read ↗

Comprehensive genomic profiling (CGP) of ovarian clear cell carcinomas (OCCC) identifies clinically relevant genomic alterations (CRGA) and targeted therapy optionsSemantic proximity Read ↗

Clinical analysis and literature review of a case of ovarian clear cell carcinoma with PIK3CA gene mutation: A case report.Semantic proximity Read ↗

PIK3R1W624R Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma.Semantic proximity Read ↗

Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma.Semantic proximity Read ↗

Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.Semantic proximity Read ↗

PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.Semantic proximity Read ↗

Molecular diagnosis in type I epithelial ovarian cancer.Semantic proximity Read ↗

Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials.Semantic proximity Read ↗

Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer.Semantic proximity Read ↗

Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinomaSemantic proximity Read ↗

High frequency of BRAF mutations and concomitant KRAS mutations in Taiwanese ovarian clear cell carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.